Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) - Drugs In Development, 2021
Summary This latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It’s caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 11, 7, 2, 43, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 2, 12 and 2 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)
Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.The most common clinical scenario for RSV is an...
Melanoma - Global Drug Forecast and Market Analysis to 2029 Summary Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029 Summary Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
The global interventional neuroradiology market is expected to reach US$ 3,254.55 Mn in 2027 from US$ 1,969.39 Mn in 2018. The market is estimated to grow with a CAGR of 5.9% from 2019-2027. Progressive aging population, increasing demand for minimally invasive procedures and rise in the prevalence of the cerebral aneurysm play vital role...
AstraZeneca Plc - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘AstraZeneca Plc - Product Pipeline Review - 2016’, provides an overview of the AstraZeneca Plc’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development...
Opportunity Analyzer: Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecast to 2025 Summary The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF - Roche’s Esbriet and Boehringer Ingelheim’s Ofev. Esbriet was the first drug to gain approval...
108 pages •
By Infiniti Research Limited
• May 2018
About Pathology Consumables Pathology consumables are laboratory commodities used for the preparation of cell or tissue samples to identify abnormalities in the sample. Technavio’s analysts forecast the Global Pathology Consumables Market to grow at a CAGR of 6.85% during the period 2018-2022. Covered...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.